Holdener E E, Bollag W
Department of Clinical Research, F. Hoffman-La Roche Ltd., Basel, Switzerland.
Curr Opin Oncol. 1993 Nov;5(6):1059-66. doi: 10.1097/00001622-199311000-00019.
This review highlights recent advances in understanding the mode of action of retinoids at the level of molecular and cellular biology in relation to the new clinical results achieved with retinoids in various malignancies. All-trans-retinoic acid has been established in the clinic as a first-line differentiation therapy for acute promyelocytic leukemia. Other retinoids, as single agents or in combination, generated interesting preliminary results in prevention of or therapy for various precancerous and cancerous lesions. These results are currently being corroborated in ongoing trials. Retinoids are emerging as a new class of anticancer agents with a new molecular target, offering new combination therapies.
本综述重点介绍了在分子和细胞生物学水平上理解维甲酸作用模式方面的最新进展，这些进展与维甲酸在各种恶性肿瘤中取得的新临床结果相关。全反式维甲酸已在临床上确立为急性早幼粒细胞白血病的一线分化疗法。其他维甲酸作为单一药物或联合用药，在预防或治疗各种癌前病变和癌性病变方面产生了有趣的初步结果。目前正在进行的试验正在证实这些结果。维甲酸正在成为一类具有新分子靶点的新型抗癌药物，提供新的联合治疗方法。
